BPC-157 vs TB-500 — research differences and combined-use literature
BPC-157 (Body Protection Compound 157) and TB-500 (a synthetic thymosin beta-4 fragment) are the two most-studied research peptides in the tissue-repair literature. They share an investigative goal — accelerated soft-tissue healing in research models — but operate by different mechanisms. BPC-157 is a 15-amino-acid synthetic gastric-juice fragment associated in the literature with VEGF-mediated angiogenesis, nitric oxide modulation, and growth-hormone-receptor interaction. TB-500 / thymosin β4 fragment is a 17-amino-acid actin-binding peptide associated with cell migration, anti-inflammatory effects, and stem-cell mobilisation. The pairing is common in published research protocols precisely because the mechanisms are non-overlapping.
Side-by-side
| BPC-157 15 mg | TB-500 10 mg | |
|---|---|---|
| Class | Synthetic gastric-juice fragment | Synthetic thymosin β4 fragment |
| Length | 15 amino acids | 17 amino acids (TB4 active region) |
| Primary mechanism | VEGF-mediated angiogenesis, NO modulation | Actin sequestration, cell migration |
| Origin tissue | Gastric juice (parent BPC) | Thymus (parent thymosin β4) |
| Research focus | Tendon, ligament, gut barrier, vascular repair | Cardiac, dermal, ocular tissue repair |
| Stability | Acetate or arginate salt — both used in research | Standard lyophilised peptide |
| Published trial status | Pre-clinical / animal model only | Phase 2 clinical (cardiac, ocular) |
What to know
- ·Both are research-use-only — neither is FDA approved.
- ·BPC-157 has a much larger volume of in-vivo animal-model literature; TB-500 has more cell-culture and a small clinical-trial footprint.
- ·Pairing is common in published research protocols — the mechanisms are independent and non-redundant.
- ·BPC-157 has both acetate and arginate salt forms; arginate has greater stability at pH variations.
- ·TB-500 is the synthetic active-region fragment; full-length thymosin β4 is structurally distinct (different molecular weight, different research applications).
Where the literature diverges
BPC-157 literature is dominated by gastrointestinal-protection, tendon-repair, and vascular-recovery models from the Sikiric / Seiwerth Croatian research groups (200+ pre-clinical papers since 1991). TB-500 / thymosin β4 literature is led by Allan Goldstein's group at George Washington University and is more cardiology- and ophthalmology-focused, with active phase 2 clinical trials for diabetic skin ulcers and severe dry eye. The geographic and disciplinary split largely explains why the two compounds rarely appear in the same trial.
FAQ
Why are they often paired in research protocols?+
The mechanisms are independent — BPC-157 (angiogenesis + NO) and TB-500 (actin sequestration + cell migration) act on different rate-limiting steps in tissue-repair models. Combined-protocol papers cite synergistic or additive effects in animal-model tendon-repair and cardiac-recovery designs.
Which has stronger published evidence?+
Volume of pre-clinical literature: BPC-157, by an order of magnitude. Clinical-trial progression: TB-500 / thymosin β4, with active phase 2 trials in cardiac and ocular indications. Different stages of the evidence pipeline.
Are they the same as actual TB4?+
TB-500 is the synthetic 17-amino-acid active-region peptide of thymosin β4. Full-length thymosin β4 is a 43-amino-acid endogenous protein. Research papers use the two interchangeably for the bioactive fragment but the molecules are not the same.
This is a research-context comparison of compound mechanism and published trial outcomes. Not medical advice. Both compounds are research-use only when sold by Omega Grade — for in vitro laboratory investigation, not human or veterinary administration.
- ResearchTB-500 10 mg
Synthetic full-length 43-residue thymosin β-4. The most abundant intracellular actin-sequestering peptide in mammalian tissues.
- ResearchBPC-157 15 mg
15-residue synthetic pentadecapeptide. Most extensively studied in rodent tendon, ligament, skin, and gastric-mucosal models.
- ResearchBPC-157 + TB-500 10/10 mg kit
The most-requested regenerative-peptide kit in the catalogue. BPC-157 and thymosin β-4 combined in a single lyophilised vial — commonly paired in prec
- Biomarkerhs-CRP 2.5 mg/L
High-sensitivity C-reactive protein at 2.5 mg/L sits in the 'intermediate cardiovascular risk' category most cardiology research uses. What it measures, what drives it, and how to interpret your number.
- ComparisonBPC-157 acetate vs arginate — salt forms compared
BPC-157 is sold as either the acetate or arginate salt. The arginate form has improved stability across pH variations; acetate is the historical default.